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Objective: To compare the efficacy and toxicity of cyclosporin A (CsA) monotherapy with CsA plus
methotrexate (MTX) combination therapy in patients with early rheumatoid arthritis (RA).
Patients and methods: 120 patients with active RA, rheumatoid factor positive and/or erosive, were
randomly allocated to receive CsA with MTX (n=60) or CsA with placebo (n=60). Treatment with CsA
was started in all patients at 2.5 mg/kg/day and increased to a maximum of 5 mg/kg/day in 16
weeks. MTX was started at 7.5 mg/week and increased to a maximal dose of 15 mg/week at week
16. Primary outcomes were clinical remission (Pinals criteria) and radiological damage (Larsen score),
at week 48.
Results: Treatment was discontinued prematurely in 27 patients in the monotherapy group (21
because of inefficacy, and six because of toxicity) and in 26 patients in the combination therapy group
(14 and 12, respectively). At week 48, clinical remission was achieved in four patients in the mono-
therapy group and in six patients in the combination therapy group (p=0.5). The median Larsen score
increased to 10 (25th, 75th centiles: 3.5; 13.3) points in the monotherapy group and to 4 (1.0; 10.5)
points in the combination therapy group (p=0.004). 28/60 (47%) of patients in the monotherapy
group v 34/60 (57%) of patients in the combination therapy group had reached an American college
of Rheumatology 20% (ACR20) response (p=0.36) at week 48; 15/60 (25%) v 29/60 (48%) of
patients had reached an ACR50 response (p=0.013); and 7 (12%) v 12 (20%) of patients had
reached an ACR70 response (p=0.11).Their was a tendency towards more toxicity in the combination
therapy group.
Conclusions: In patients with early RA, neither CsA plus MTX combination therapy nor CsA
monotherapy is very effective in inducing clinical remission. Combination therapy is probably better at
improving clinical disease activity, and definitely better at slowing radiological progression. Combina-
tion therapy should still be compared with methotrexate monotherapy.
Both early diagnosis and early treatment with diseasemodifying antirheumatic drugs (DMARDs) are impor-tant in patients with rheumatoid arthritis (RA) to inhibit
radiological progression and to prevent long term functional
loss.1–9 Methotrexate (MTX) is considered one of the most
powerful conventional DMARDs which may retard
radiological progression,10–14 and has an acceptable toxicity
spectrum.14–16 These characteristics make MTX the anchor
drug in the treatment of RA, and in a number of studies in
early RA MTX was used as one part of a DMARD
combination.15–18 Cyclosporin A (CsA) has proved to be
effective in both advanced and early RA.18–25 The toxicity,which
is particularly increased in the presence of serum creatinine
and hypertension, is considered manageable if dosage
guidelines are strictly maintained.20 26–28 In a number of studies
it has been suggested that radiological progression is
retarded by CsA in comparison with placebo or other
DMARDs.29–31
Because both drugs have different mechanisms of action,
and their toxicity patterns do not overlap, the combination of
MTX with CsA may offer complementary efficacy.32 Patients
with advanced RA and a poor response to MTX have shown
significant clinical improvement after the addition of CsA,18
and the drug combination was tolerated well. These results
were a basis for investigating the potential of CsA in combina-
tion with MTX in achieving clinical remission and in slowing
radiological progression in patients with early RA. We
proposed the hypothesis that patients with early RA and fac-
tors indicating a poor prognosis8 would gain most from early
aggressive intervention by combination therapy
The purpose of this study was to investigate whether the
combination of MTX and CsA is more effective than CsA
monotherapy in inducing clinical remission and slowing
radiological progression in patients with early RA
PATIENTS AND METHODS
The study was conducted in 16 centres throughout the Neth-
erlands between November 1996 and November 1999. Patients
were eligible for the study if they met the following inclusion
criteria: RA according to the 1987 American Rheumatism
Association criteria,33 age between 18 and 70 years, and a dis-
ease duration of less than three years. Patients had to have
factors indicating a poor prognosis, defined as at least one
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erosive lesion and/or a positive serum rheumatoid factor test
(Latex test, and/or Rose-Waaler test, and/or IgM rheumatoid
factor enzyme linked immunosorbent assay (ELISA)). Pa-
tients had to have active disease, defined as at least three out
of four activity criteria: six swollen joints (out of 66); six ten-
der joints (out of 68); an erythrocyte sedimentation rate (ESR)
of at least 28 mm/1st h, and/or a C reactive protein (CRP) of at
least 20 mg/l; a global assessor’s score of disease activity
(ranging from 1=no activity to 5=severe activity) of at least 4.
Only patients with a normal renal function (a creatinine
clearance as calculated by the Cockroft formula34 of at least 80
ml/min for men and of at least 70 ml/min for women) were
allowed to enter the study.
Patients were excluded from the study if they had received
previous treatment with CsA or MTX or more than one other
DMARD, and if treatment with any DMARD had been for
longer than three months. Other exclusion criteria were a
white blood cell count of <3×109/l; platelets of <100×109/l;
serum aspartate aminotransferase (AST), serum alanine
aminotransferase (ALT), or bilirubin levels exceeding twice
the upper limit of normal; a systolic blood pressure of >160
mm Hg and a diastolic blood pressure >90 mm Hg; a history
of hypertension (treated or untreated) or malignancy or
epilepsy; the presence of a chronic infection or gastric duode-
nal disease; and the use of drugs with a known interaction
with CsA or with MTX.
Oral corticosteroids were not permitted and non-steroidal
anti-inflammatory drugs were only permitted if the dose was
stable during the two weeks before randomisation. Intra-
articular injections were allowed during the study. For a period
of four weeks injected joints were counted as swollen and
tender.
Study design and monitoring
The study protocol was approved by the medical ethics
committees of the participating hospitals and all patients gave
written informed consent.
After providing informed consent and after a four week
screening period, patients were randomly assigned to one of
the two study arms. Randomisation was performed by a com-
puter generated list. Patients received the study drug for a
maximum of 48 weeks.
In one study armCsAwas combinedwithMTX (combination
therapy group) and in the other arm CsA was combined with a
placebo (monotherapy group). Folic acid 1 mg/day was
prescribed to all patients. CsA was provided by the patient’s
regular pharmacist on prescription. The placebo was produced
by the pharmacy of the VUMedical Centre and was packed and
made indistinguishable from MTX at that centre. CsA was
started at a dose of 2.5 mg/kg/day, and was increased in three
steps to a maximum of 5mg/kg/day during the first 16 weeks. A
period of at least four weeks between two CsA dose increments
was required. MTX or placebo was started at a dose of 7.5
mg/week, which was kept constant during the first 16 weeks of
the study and was increased to 15 mg/week at week 16.
The CsA and/or MTX (placebo) study drug dosage was only
increased if the patient did not meet the Pinals criteria for
clinical remission, and if safety guidelines for dosing CsA and
MTX were met.28
At each visit (every two weeks during the first 12 weeks;
every four weeks thereafter) blood pressure was measured,
laboratory safety tests (biochemistry and haematology) were
performed, and side effects were monitored.
The CsA dosage was decreased by 50 mg/day if the serum
creatinine level had increased bymore than 30% from baseline
at two consecutive visits and/or if blood pressure exceeded
Table 1 Patient characteristics at baseline. A 48 week placebo controlled trial
comparing cyclosporin A (CsA) monotherapy with CsA and methotrexate (MTX)
combination therapy in patients with RA with poor prognosis
Characteristic CsA plus MTX (n=60) CsA (n=60)
Age (years) 52.5 (10.6)* 51.2 (11.6)*
Disease duration (months) 2.9 (3.5)* 2.7 (5.7)*
Women 37 (62)† 42 (70)†
Erosive at start of study 32 (53)† 27 (45)†
Rheumatoid factor positive at start 56 (93)† 58 (97)†
DMARD used before study (patients) 11 (18)† 6 (10)†
*Mean (standard deviation); †Number of patients (percentage).
Table 2 Total number adverse events related to study drug
Kind of adverse event
Group
CsA plus MTX CsA
A period with >30% raised serum creatinine 47 42
A period with hypertension 38 38
Gastric intestinal complaints 28 26
Hypertrichosis 13 19
Headache 11 13
Raised serum potassium 10 4
Liver enzyme disturbances 7 7
Paraesthesias 6 7
Gingivitis 5 8
Fluid retention 5 3
Tremor 4 2
Metrorrhagia 3 1
Fatigue 1 3
Others 19 19
Total 197 192
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160/95 mm Hg at two consecutive visits. Treatment with a cal-
cium blocking agent to lower blood pressure without CsA dose
reduction was allowed.
The MTX dosage was decreased by 7.5 mg if leucopenia
(<3×109/l) or thrombocytopenia (<100×109/l) developed or if
there was an increase of ALT or AST by more than twice the
upper limit at two consecutive visits.
End points
The primary end points were clinical remission according to
the Pinals criteria35 with a minor modification,35 and radiologi-
cal damage according to the Larsen modified Larsen score.36 37
Both primary end points were assessed at week 48. In brief,
patients were considered to be in clinical remission if they met
five of the six following criteria: duration of morning stiffness
not exceeding 15 minutes; no fatigue; no joint pain (by
history); no joint tenderness or pain on motion; no soft tissue
swelling in joints or tendon sheaths; ESR <30 mm/1st h
(female) or <20 mm/1st h (male)/or a CRP <10 mg/l. An x ray
examination was made at baseline and after 48 weeks, and x
rays were scored by two observers unaware of the study drug,
but aware of the chronological order. The mean score of the
two observers was taken as the Larsen score. If radiographs
were missing for a patient, only scores of one time point were
used for calculating median scores for the whole group at that
time and these scores were not used for calculating
progression of radiological damage.
Secondary outcome variables were the disease activity
measures of the World Health Organisation/International
League of Associations for Rheumatology (WHO/ILAR) core
set.38 The measures were assessed at four week intervals and
included a swollen joint count (66 joints), a tender joint count
(68 joints), pain (10 cm visual analogue scale (VAS) with worst
imaginable pain and no pain at all as extremes), fatigue (10 cm
VAS with extreme fatigue and no fatigue as extremes),
patient’s and assessor’s global assessment of disease activity
(five point Lickert scale ranging from no disease activity to
severe disease activity), duration of early morning stiffness (in
minutes), ESR (Westergren’s method), and CRP. At 0, 24, and
48 weeks functional ability was measured (the validated Dutch
version of the Health Assessment Questionnaire; scores from 0
(best) to 3 (worst)). Secondary end point variables were used
to calculate the number of patients meeting the American Col-
lege of Rheumatology (ACR) criteria for clinical improvement
(ACR20, ACR50, and ACR70)39 at weeks 24 and 48.
Premature discontinuation
The study protocol required patients to stop taking the study
drug for the following reasons: if two consecutive dose reduc-
tions of CsA or MTX, or both,were necessary; if the patient did
not meet the ACR20 criteria for clinical improvement39 40 at
week 24; if the study drug was discontinued for more than two
weeks; if an adverse event occurred that in the opinion of the
treating rheumatologist required discontinuation of CsA or
MTX; and/or if consent was withdrawn by the patient. After 48
weeks of treatment with the study drug, patients could choose
to continue their drug in an open fashion. If the study drug
was discontinued before week 48, the treating rheumatolo-
gists were free to make their choice of further treatment.
Sample size
The expected rise in erosion score was 5 (SD 6) during 48
weeks. The required sample size to detect a difference of 3 (6)
in erosion score between the monotherapy and the combina-
tion therapy group (α=0.05, power=0.80) is 60 patients in
each study arm.
In advance a clinical remission rate of approximately 10% in
the monotherapy group and 30% in the combination therapy
group (a difference of 20%) was assumed as clinically relevant.
To detect such a difference with a power of 0.90 (two sided
α=0.05), a sample size of 60 patients in each arm was neces-
sary.
Analysis
An intention to treat analysis was performed as the primary
mode of analysis. If patients had stopped treatment prema-
turely, the last value obtained was carried forward and used in
the analysis. An analysis of those completing the study was
performed as a secondary analysis. Differences in efficacy
measures were analysed by comparing changes from baseline.
Within-group differences were tested using t test statistics for
paired observations; differences between treatment groups
were statistically tested using t test statistics for unpaired
observations. Parametric and non-parametric tests were used
depending on distribution of data. Dichotomous outcomes
(frequencies of adverse events, premature discontinuations,
ACR responses) were compared using Fisher’s exact test or χ2
test, if appropriate. All calculations were done using SPSS
software.
RESULTS
Patients’ characteristics
A total of 120 patients were included in the study. Almost all
patients were rheumatoid factor positive, and a considerable
number already had erosions at the start of the study (table 1).
The two groups were fairly well balanced, but the combination
therapy group had a higher swollen joint count and a higher
ESR at baseline.
Figure 1 Radiological progression. Median Larsen scores (25th,
75th centiles) at baseline and after 48 weeks of treatment are given
in each group. The p value refers to the between-group difference in
change after 48 weeks. Numbers are the number of patients on
which the analyses were based. Figure 2 Swollen joint count. Course of swollen joint count over
time. Mean numbers of swollen joints in each group at different times
are shown.
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Course of the study
The CsA dose at 24 weeks was 3.5 (1.1) (mean (SD))
mg/kg/day in the monotherapy group and 3.1 (1.2) mg/kg/day
in the combination therapy group (p=0.107 for the between-
group difference). The MTX dose at week 24 was 13.7 (3.0)
(mean (SD)) mg/week in the combination therapy group and
the placebo dose 13.9 (2.6) in themonotherapy group (p=0.73
for the between-group difference) At week 24, 38 patients
(63%) in the combination therapy group and 40 (67%)
patients in the monotherapy group had achieved an ACR20
response and thus continued the study drug according to the
protocol.
The mean CsA dosage at 48 weeks was 2.8 (1.0) mg/kg/day
in the monotherapy group and 2.7 (1.3) mg/kg/day in the
combination therapy group (p=0.89). The dose of MTX was
13.0 (3.5) mg/week in the combination therapy group and of
placebo 14.3 (2.2) in the monotherapy group (p=0.07).
Adverse events
A total number of 197 adverse events in the combination
therapy group and 192 adverse events in the monotherapy
group were considered related to the study drug (table 2).
None of the adverse events had occurred significantly more
frequently in one of the groups. After 48 weeks of treatment
mean serum creatinine had increased from 74 (12) µmol/l
(mean (SD)) to 89 (17) µmol/l in the monotherapy group
(p<0.001), and from 72 (11) µmol/l to 90 (19) µmol/l in the
combination therapy group (p<0.0001) (p=0.28 for the
difference between the groups). Systolic blood pressure
increased from a mean of 131 mm Hg to 139 mm Hg in the
monotherapy group and from 134 mm Hg to 143 mm Hg in
the combination therapy group. Diastolic blood pressure
increased from a mean of 80 mm Hg to 84 mm Hg in the
monotherapy group and from 79 to 84 mm Hg in the combi-
nation therapy group. Fifteen patients in the monotherapy
group and six patients in the combination therapy group
received an antihypertensive drug. Sixteen serious adverse
events (six in the monotherapy group and 10 in the combina-
tion therapy group) had occurred during the study period: five
acute cardiovascular events, three exacerbations of the RA
needing admission to hospital, two cases of malignancy, and
one case each of urosepsis, Alzheimer’s disease, anaemia, sig-
moid perforation, postmenopausal vaginal bleeding, and
exacerbation of chronic bronchitis. None of these adverse
events were thought to be related to the study drug by the
judging physician.
Premature discontinuations
Twenty seven patients in the monotherapy group (21 because
of lack of efficacy and six because of toxicity) and 26 patients
in the combination therapy group (14 because of lack of effi-
cacy and 12 because of toxicity) had stopped treatment during
the study. In the monotherapy group, treatment was
discontinued prematurely by 11 patients before week 24, 10 at
week 24 because of the protocol, and six after week 24. In the
combination therapy group the numbers of patients discon-
tinuing were 15, 10, and 1, respectively. Between-group differ-
ences for the numbers discontinuing the study were not
statistically significant. Hypertension or an increase in serum
creatinine, or both, were more often a reason for discontinua-
tion in the combination therapy group (nine patients v two
patients; p=0.05).
Efficacy end points
At 48 weeks, six patients (10%) in the combination therapy
group and four patients (7%) in the monotherapy group
(p=0.5 for the between-group difference) fulfilled the Pinals
criteria for clinical remission
Radiological damage showed significantly more progression
in the monotherapy than in the combination therapy group
(fig 1). Radiographs at 48 weeks were missing in three
patients in the monotherapy and two patients in the
combination therapy group. At the start, the median Larsen
score was 2.5 (25th, 75th centile: 0.5; 5.5) points in the mono-
therapy group and 2.0 (0; 5.5) points in the combination
therapy group. After 48 weeks, the Larsen score had increased
to 10 (3.5; 13.3) points in the monotherapy group and to 4
(1.0; 10.5) points in the combination therapy group. This
between-group difference was significant (p=0.004).
At baseline the total number of erosive joints was 0 (0; 1) in
both groups. At week 48 the total number of erosive joints had
increased to 2.5 (1; 5) in the monotherapy group and to 1.0 (0;
3) in the combination therapy group (p=0.01 for the between
group difference). At baseline the total number of erosions
was 0 (0; 1) in both groups. At week 48 the total number of
erosions had increased with 3.5 (1; 7.5) in the monotherapy
group and 1.5 (0; 4) in the combination therapy group
(p=0.02 for the between-group difference).
Table 3 Disease activity measures. Changes from baseline after 24 weeks’
treatment. Results are shown as mean (SD)
CsA plus MTX group (n=60) CsA group (n=60)
p Value*Baseline
Change at 24
weeks Baseline
Change at 24
weeks
Swollen joint count 21 (10) −12 (10) 17 (7) −8 (9) 0.05
Tender joint count 26 (13) −13 (12) 24 (12) −13 (9) 0.59
ESR (mm/1st h) 53 (33) −15 (32) 46 (27) −5 (27) 0.09
C reactive protein (mg/l) 51 (45) −15 (19) 49 (44) −19 (26) 0.45
HAQ score 1.43 (0.69) −0.90 (0.67) 1.36 (0.63) −0.87 (0.65) 0.80
VAS for pain (cm) 5.0 (2.1) −2.0 (2.5) 4.8 (2.4) −2.3 (2.7) 0.75
*For the difference in change from baseline between both groups.
Figure 3 Improvement according to ACR criteria. Percentages of
patients fulfilling ACR criteria for 20%, 50% and 70% improvement
at week 48. p Values refer to between-group differences.
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All separate parameters of disease activity had improved
significantly in both groups during the study, except the ESR
in the monotherapy group. Figure 2 shows an example. Apart
from the decrease in ESR, the between-group differences for
improvement in disease activity measures were not statisti-
cally significant, but there was always a trend towards more
improvement in the combination therapy group (table 3,
intention to treat analysis). Intra-articular injections were
given to 11 patients (21 injections) in the monotherapy group
and 18 patients (28 injections) in the combination therapy
group respectively. Figure 3 shows the numbers of patients
with different levels of ACR responses. In five of the 120
patients it was not possible to calculate clinical responses
because of missing values. These patients were considered
non-responders. Thirty four of the 60 patients in the
combination group (57%) and 28/60 (47%) patients in the
monotherapy group had achieved an ACR20 response at week
48 (p=0.36 for the between-group difference). Twenty nine
patients (48%) v 15 patients (25%) had achieved an ACR50
response (p=0.013), and 12 patients (20%) v 7 patients (12%)
had achieved an ACR70 response (p=0.32).
DISCUSSION
It can be concluded from this study that a DMARD combina-
tion of CsA and MTX is better than CsA monotherapy in slow-
ing down radiological progression. Whether the combination
is more effective than CsA monotherapy in improving disease
activity can be disputed. Clearly, trends in all clinical measure-
ments support the superiority of combination therapy, but
proportions of ACR20 responses are not significantly different
between combination and monotherapy.
The primary end point of this study was clinical remission
at 48 weeks of treatment, and it is obvious that both
monotherapy and combination therapy failed to induce clini-
cal remission in a substantial proportion of patients. However,
the Pinals criteria are difficult to meet, and other studies with
conventional DMARD combinations have also reported low
numbers of clinical remissions.17
Despite the absence of contrast in proportions of patients
with clinical remission, we found a highly significant
difference in radiological progression in favour of the
combination therapy group. An early deceleration of radiologi-
cal progression is relevant for long term outcome. Radiological
progression has been shown to be related to long term
functional outcome.1
Radiological progression is considered to be a consequence
of inflammatory processes, and the between-group difference
in radiological progression in the absence of statistically
significant differences in clinical disease activity was some-
what unexpected. A possible explanation may be that a type II
error is operative. There are strong indications that patients in
the combination therapy group had better clinical improve-
ment than patients in the monotherapy group, but that the
study was insufficiently powered to detect small differences.
The inability to detect small differences is not a shortcoming
of the study. Our randomised controlled trial (RCT) was pow-
ered to detect relevant differences in the proportion of patients
with clinical remission, not in the proportion of patients with
an ACR20 response.Higher response rates in the control group
(CsA monotherapy in our study) deflate the power of an RCT
to detect treatment effects in dichotomous outcomes, as dem-
onstrated here. Our study can therefore neither prove nor
exclude differences in clinical efficacy between the groups. As
a consequence, significant deceleration of radiological pro-
gression may very well be due to non-significant but clinically
relevant differences in disease activity between both groups.
The results suggest that the quality rather than the quantity of
clinical responses differs between the groups.
An obstacle in positioning the efficacy of the combination of
CsA and MTX is the absence of a control arm with MTX
monotherapy.We tried to find additional reported evidence for
the effects of MTX alone in patients with RA. Despite the fact
that a number of RCTs have included an MTX monotherapy
arm, differences in patient population, MTX dose, and dose
strategy, study duration, and type of assessments made it
impossible to compare the results appropriately. Therefore we
cannot conclude that the combination of MTX and CsA is bet-
ter than MTX monotherapy. Limited evidence that CsA plus
MTX combination therapy adds to the effect provided by MTX
alone is found in a study by Marchesoni et al.31 In that
randomised trial in early RA, CsA/MTX combination therapy
was compared with MTX monotherapy. The data in that study
showed a higher ACR20 response and significantly lower
radiological progression in the combination therapy group
than in the group receiving MTX alone.31 The combination
MTX/CsA should also be compared with other combination
therapies in early RA. The COBRA trial (1993–97)17 focused on
patients with RA with similar disease duration, similar
prognostic factors, and similar disease activity. In the COBRA
study patients were treated either with sulfasalazine mono-
therapy or with a step down combination regimen with tem-
porary high dose prednisolone, low dose MTX, and mainte-
nance sulfasalazine. The ACR20 criteria were met by 72% of
the patients in the COBRA combination therapy group and the
ACR50 improvement criteria were met by 49% of the patients
at week 28. In our study ACR20 improvement criteria were
met by 63% of the patients in the combination therapy group
and 40% had met the ACR50 criteria at week 24. These results
suggest that the clinical effectiveness of the MTX/CsA combi-
nation may be compared with the COBRA combination
therapy in patients with early RA.
A second obstacle in positioning the combination of MTX
and CsA in clinical practice may be increased toxicity. All
adverse events, either serious or not, were similarly divided
among both groups, but there was an obvious trend towards
more premature discontinuations for toxicity in the combina-
tion therapy group. It is relevant to mention the significantly
higher proportion of patients withdrawing because of renal
function loss and hypertension in the combination therapy
group, emphasising that some increased toxicity cannot
entirely be excluded.
A glance at table 2 shows that more than 50% of all reported
adverse events are CsA related (creatinine rise, hypertension,
hypertrichosis, gingivitis), whereas only a minority are MTX
related (liver enzyme disturbances) and one might expect a
more advantageous toxicity spectrum in patients treated with
MTX alone. Various studies have looked at the relevance of
CsA related renal function disturbances, hypertension, and so
called CsA nephropathy. The common conclusions,which have
led to recommendations, are that clinically relevant CsA
nephropathy can be prevented by avoiding higher doses of
CsA,27 and by not onlymonitoring serum creatinine but also by
taking proper action when there is renal function loss. The
effects of adding MTX to CsA on the renal function and blood
pressure, however, have never been thoroughly investigated
beyond the RCT. Any additional type of CsA related toxicity
which may be due to the addition of MTX should be weighed
against the benefits of this DMARD combination in efficacy.
In summary, this study of the efficacy of CsA plus MTX
combination therapy in comparison with CsA monotherapy
suggests they are equivalent in their induction of clinical
remission. Post hoc analyses indicate that the study was prob-
ably underpowered to determine differences in induction of
clinical remission. The results showed slight superiority of the
drug combination in improving clinical disease activity, and
definite superiority of the combination in retarding radiologi-
cal progression.
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